XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock Option and Grant Plan (Tables)
9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Summary of Stock-based Compensation Expense

Stock-based compensation expense recorded as research and development and general and administrative expenses in the condensed consolidated statements of operations and other comprehensive loss is as follows (in thousands):

 

 

Three Months Ended
September 30,

 

 

Nine Months Ended
September 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Research and development

 

$

13,859

 

 

$

7,554

 

 

 

38,581

 

 

 

17,049

 

General and administrative

 

 

8,350

 

 

 

5,414

 

 

 

23,241

 

 

 

11,019

 

Total stock-based compensation expense

 

$

22,209

 

 

$

12,968

 

 

$

61,822

 

 

$

28,068

 

Summary of Option Activity Under Equity Award Plans

The following table provides a summary of option activity under the Company’s equity award plans:

 

 

Number
of options

 

 

Weighted
average
exercise
price

 

Outstanding at December 31, 2021

 

 

6,034,192

 

 

$

32.40

 

Granted

 

 

2,051,846

 

 

 

62.32

 

Exercised

 

 

(369,444

)

 

 

5.33

 

Forfeitures

 

 

(109,531

)

 

 

55.89

 

Outstanding at September 30, 2022

 

 

7,607,063

 

 

 

41.45

 

Exercisable as of September 30, 2022

 

 

3,421,139

 

 

 

24.52

 

Summary of Restricted Stock Activity The following table summarizes the Company’s restricted stock activity:

 

 

Shares

 

 

Weighted-
average grant
date fair
value

 

Unvested as of December 31, 2021

 

 

1,126,206

 

 

$

74.32

 

Issued

 

 

937,725

 

 

 

53.52

 

Vested

 

 

(379,287

)

 

 

51.00

 

Forfeited

 

 

(36,865

)

 

 

75.65

 

Unvested as of September 30, 2022

 

 

1,647,779

 

 

$

67.82